Study checking omaveloxolone health effects during pregnancy and breastfeeding
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people with Friedreich's ataxia who took omaveloxolone during pregnancy or while breastfeeding, to check how the drug affected their health and their baby's health. It helps doctors understand the safety of this treatment for mothers and babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took the study drug (omaveloxolone, also called BIIB141) for Friedreich's ataxia while you were pregnant or breastfeeding.
- If you were pregnant, the drug was taken anytime from 12 days before conception until your baby was born.
- If you were breastfeeding, the drug was taken anytime from when your baby was born until they turned 1 year old or stopped nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term safety of omaveloxolone (BIIB141) for people with Friedreich's ataxia. You can join if you are just starting this medicine or have been taking it for less than a year.
This study looks at whether omaveloxolone (a medication) can help improve swallowing problems in people with Friedreich's ataxia. If you have been taking omaveloxolone for at least 6 months, your data may help researchers understand if it helps with swallowing.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
This study tests a new medicine called DT-216P2 in healthy people to find a safe dose. It is a first step in developing a treatment for Friedreich ataxia, a genetic condition that affects movement and balance.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.